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The LKB1 tumor suppressor kinase is an activator of the AMP-activated protein kinase (AMPK), a
metabolic gauge that responds to variations of cellular energetic levels by favoring catabolic versus
anabolic processes. Recent studies have provided substantial evidence that LKB1 and AMPK control
cell polarity from invertebrates to mammals. This review examines how the LKB1–AMPK pathway,
in conjunction with other positional signals, converts energy-sensing information into the activa-
tion of Myosin II to maintain epithelial-cell architecture but also to complete cell division. This
molecular link between polarity and metabolism may constitute an ancient stress-response protec-
tive mechanism that was co-opted for tumor suppression during evolution.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. LKB1 and AMPK are two components of an epithelial polarity
pathway
Since its ﬁrst identiﬁcation in a genetic screen for mutants
affecting the cytoplasmic partitioning of Caenorhabditis elegans em-
bryo, the function of LKB1 has been linked to the regulation of cell
polarity [1]. In this organism, par-4, the ortholog of LKB1, is re-
quired for the ﬁrst asymmetric divisions during early stages of
embryonic development. This role is highly reminiscent to what
is observed in Drosophila oocyte where LKB1 is needed for ante-
rior–posterior axis determination [2]. LKB1 is also involved in the
establishment of polarity in other cell types including neurons
and epithelial cells in invertebrates and vertebrates [2–5]. Thus,
LKB1 is a textbook example of the conservation of cell polarity reg-
ulators between distant organisms. As discussed in this review, re-
cent results further indicate that the complete LKB1 signaling
network has been conserved across evolution but molecular events
downstream of LKB1 vary according to the tissue considered and
its physiological microenvironment.
In mammals, LKB1 encodes a master kinase that phosphorylates
and activates 13 members of the AMPK-Related Kinases (ARK) [6].
Several studies have linked the polarity functions of LKB1with its ki-
nase substrates. For instance, LKB1 requirement for either C. eleganschemical Societies. Published by E
(V. Mirouse), Marc.Billaud@embryo asymmetric division or Drosophila oocyte polarity is associ-
ated to its ability to activate PAR-1 (called MARK-1 to MARK-4 in
mammals), whereas it activates the SAD/BRSK kinases to induce
neuron polarization [1,2,4,7]. In epithelial cells, the polarizing activ-
ity of LKB1 is relayed through PAR-1/MARK, which modulates the
functions of several proteins involved in epithelial morphogenesis
[8,9]. But besides PAR-1, a series of four papers has now come to
the striking conclusion that another LKB1 target, AMPK (AMP-
dependent activated protein kinase), is a key regulator of epithelial
polarity [10–13]. AMPK is a metabolic sensor that maintains energy
homeostasis by switching off ATP-consuming anabolic pathways
and switching on catabolic pathways [14].
Two studies report that AMPK is required for tight junction (TJ)
assembly in MDCK cells [12,13]. This cell line is a classical model
for epithelium formation in which the assembly of TJs can be pro-
moted by increasing extracellular calcium concentration (so called
calcium switch) [15]. Both groups found that the calcium switch
induces AMPK catalytic stimulation and that this activation was
necessary and sufﬁcient for TJ assembly. However, it is worth not-
ing that in these cells, LKB1 is probably not the only AMPK activat-
ing kinase and this activity might also involve CaMKKb
(Calmodulin-dependent Kinase Kinase beta), a known AMPK ki-
nase that responds to the variation of calcium concentration [16–
18]. Alternatively, the effect of calcium could be linked to its
requirement for the assembly of Adherens Junctions, which recruit
LKB1 and regulate its activity through a mechanism that is still
uncompletely understood [19].lsevier B.V. All rights reserved.
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quired for epithelial polarity in Drosophila [10,11]. Null mutations
of AMPK lead to a strong polarity phenotype with defects affecting
both the embryonic ectoderm and the follicular epithelium in the
adult ovary, although the phenotype of the latter depends on nutri-
tional conditions. In both tissues, LKB1 is required for AMPK activa-
tion. Since invertebrate epithelium development does not rest on
TJ assembly, these results suggest a broader role for AMPK in polar-
ity establishment than solely the assembly of these junctions [20].
In agreement with this idea, energetic stress induces, in a AMPK
dependent manner, polarization of LS174T, a human cell line de-
rived from colorectal tumor [10]. It had been previously shown
that these cells can be polarized by the activation of LKB1, even
in the absence of intercellular contacts [3]. Moreover, LKB1 and
AMPK have been recently implicated in the formation of the rodent
bile canalicular network that requires hepatocyte polarization [21].
Thus, LKB1 and AMPK are two components of a novel pathway in-
volves in the establishment and maintenance of epithelial polarity
in various tissues and organisms.2. Downstream and parallel actors of the LKB1/AMPK polarity
pathway
Although many questions are still unresolved, signiﬁcant pro-
gress have been done in the understanding of the LKB1/AMPK
polarity pathway. The identiﬁcation of Myosin II as the main out-
put downstream of AMPK is one of these major advances [10]. In-
deed, AMPK is required in Drosophila embryo and in LS174T cells
for Myosin II activation. This activation implicates the phosphory-
lation of its regulatory light chain (referred as MRLCII) on Serine 19
(or 22 in ﬂy), which is the major site of its regulation. This event
seems sufﬁcient to explain the function of AMPK in epithelial
polarity. Accordingly, expression of a MRLCII protein with a phosp-
homimetic mutation replacing Ser19 rescues the polarity defects of
AMPK or LKBI mutants in Drosophila embryo, and induces polariza-
tion of LS174T cells. Thus, these ﬁndings indicate that a polarity
pathway connecting LKB1 to Myosin II activation is operating in
cells. It was initially proposed that this molecular link was done
in the shortest way possible with AMPK phosphorylating directly
MRLCII [10]. It was, however, surprising for at least two main rea-
sons. Firstly, as far as we know, AMPK phosphorylates Ser/Thr that
are in a relatively well-deﬁned consensus sequence and the MRLCII
phosphorylation site does not ﬁt this motif [22]. Secondly, several
different kinases that phosphorylate this site have already been
identiﬁed, which would imply that all of these MRLCII kinases
are either not expressed or inactive when AMPK is required to acti-
vate Myosin II. However, the idea of a direct link between AMPK
and MRLCII has been recently challenged [23]. This study has re-
ported that the commercial puriﬁed AMPK protein used to show
the direct phosphorylation on MRLCII was contaminated with
other kinases and that homogeneously puriﬁed AMPK did not efﬁ-
ciently phosphorylate MRLCII in vitro. Therefore, it is very likely
that the regulation of Myosin II by AMPK is indirect and could in-
volve an already identiﬁed MRLCII kinase as an intermediate. This
idea is sustained by a recent study, although additional analyses
are required to precisely deﬁne how AMPK induces Myosin II acti-
vation [18]. Alternatively, AMPK could control the dephosphoryla-
tion of MRLCII. One member of the ARKs, NUAK1, phosphorylates
and inactivates one of the regulatory subunits of the myosin phos-
phatase, thus suggesting that AMPK could perform a similar type of
regulation [24].
Besides LKB1/AMPK/Myosin II activation, another branch of this
pathway has been identiﬁed in Drosophila. The Dystroglycan (Dg)
complex is an important link between the actin cytoskeleton and
the extra-cellular matrix (ECM). This complex is found on the basalside of epithelial cells where it interacts with the basement mem-
brane [25,26]. Results obtained in mammals are in agreement with
a Dg function in epithelium morphogenesis although its involve-
ment in cell polarity has not been described yet [27]. Dg is re-
quired for apical basal polarity in ﬂy follicle cells but only under
conditions of energetic stress [28]. The phenotype of Dg mutants
is very similar to the one of AMPK or LKB1. However, Dg loss of
function does not affect AMPK activation and the mutant pheno-
type cannot be rescued either by the expression of phosphomimet-
ic forms of AMPK or MRLCII. Further analyses revealed that, Dg is
required for Myosin II localization. In Dg mutant cells, Myosin II is
mainly localized on the basal side instead of a being enriched at
the apical pole. It appears that Dg requires the interaction with
Perlecan, one of its ligands in the basement membrane, to exert
its function in epithelial polarity. In this model, Dg probably pro-
vides positional information indicating where the basal domain
should be formed in epithelial cells. Thus, it appears that LKB1
and AMPK activate indirectly Myosin II that is required, at least
in some contexts, for epithelial polarization (Fig. 1). In parallel,
Dg, via its interaction with the basement membrane, controls the
localization of Myosin II, probably acting as a polarity cue in this
process.
3. The LKB1 polarity pathway: redundancy and robustness
The acquisition and maintenance of cell polarity is essential for
the integrity and the function of an epithelium, thus suggesting
that evolution may have set up several parallel mechanisms to
achieve a robust establishment and maintenance of epithelial
polarity. Data obtained over the last three years on LKB1 and AMPK
support this view.
A ﬁrst level of redundancy that may contribute to the pathway
robustness is the activation of AMPK. In ﬂy and in LS174T cells, the
activation of AMPK depends on LKB1 whereas it seems to also in-
volve CaMKKb in MDCK cells. Therefore, it seems likely that CaM-
KKb and LKB1 act redundantly in some tissues or under some
speciﬁc physiological contexts.
Another potential source of redundancy lies at the level of LKB1
targets since several of the ARKs are either involved in cell polarity
or morphogenesis. Moreover, the substrates of these kinases are
phosphorylated on sites that are similar in terms of amino-acid se-
quence. These observations suggest that different ARKs could
phosphorylate the same substrates. However, no example of such
redundancy at the level of ARK substrate phosphorylation has been
described to date (except between paralogs, e.g. AMPK1 and
AMPK2). Moreover, genetics experiments indicate an absence of
redundancy between AMPK and PAR-1 in Drosophila epithelial cells
(Mirouse, unpublished data).
Finally, intriguing observations indicate that AMPK require-
ment in polarity depends on the tissue type and on physiological
conditions. Accordingly, AMPK mutant analyses in Drosophila
have revealed that primary epithelium polarization in embryo
is disrupted without any restriction of environmental conditions
[10]. However, in follicular epithelium, the loss of polarity of
AMPK mutant cells is observed only when ﬂies are sugar starved
[11]. Moreover, in AMPK mutant, neuroepithelial cells of the
Drosophila eye keep their polarity even under energetic stress,
despite other kinds of defects [29]. These differences could be
explained, if we hypothesize the existence of one or several
signaling pathways redundant with the LKB1/AMPK network
and with different level of activity depending on the develop-
mental and physiological context. In follicle cells, Myosin II is
not required under normal conditions for polarity, thus suggest-
ing that redundancy takes place downstream of this molecular
motor (Fig. 1) [30]. Future investigations will provide insights
on this important question.
Fig. 1. Model of the LKB1/AMPK polarity pathway. AMPK is required indirectly for the activation of the Myosin II and this event is sufﬁcient to explain AMPK function in
epithelial polarity. However, how LKB1–AMPK lead to Myosin II activation is unknown. In parallel, Dystrogylcan (Dg) complex, via its interaction with the ECM protein
Perlecan (Pcan) present in the basement membrane, acts as polarity cue controlling the localization of the Myosin II. At least in some contexts, this AMPK/LKB1 pathway
works redundantly to an other polarity pathway sensitive to the metabolic state of the cells.
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cellular stress
The coupling between energetic metabolism and basic cellular
functions, such as cell polarity, raises the idea that it may consti-
tute an ancestral pathway that was selected during evolution
allowing the polarized migration of organisms towards a source
of nutrients. The integration of metabolic cues and active direc-
tional propelling mechanisms may have increased the adaptive va-
lue of these species. Since recent studies have established that the
same polarity molecular toolkit is used for oriented migration and
for the formation of the apical–basal axis, one might speculate that
this biological device has been reused in various developmental
contexts [31].
In this regard, it is worth noting that vertebrate embryos devel-
op in low-oxygen environment, conditions that switch on the
LKB1–AMPK pathway [32]. Thus, the long-range cell migrations
that occur during embryonic development may require the
LKB1–AMPK–Myosin II pathway. Such a mechanism could account
for the severe malformations of mouse embryos carrying muta-
tions inactivating both AMPK alpha subunit genes or LKB1
[33,34]. In addition, the LKB1–AMPK polarity pathway may have
been co-opted in adult tissues to respond to other kind of biologi-
cal insults. Accordingly, a recent study has provided evidence that
lymphocytes accelerate the formation of epithelial TJ, a mechanism
dependent of AMPK [35]. Interestingly, in these conditions, the
activation of AMPK was independent of the cellular ATP/AMP lev-
els, but was triggered by the pro-inﬂammatory cytokine TNF-a.
Thus, a seemingly function of AMPK could be the protection of
mucosal epithelium architecture in response to the recruitment
of activated lymphocytes at sites of infection, a mechanism that
would interfere with the spreading of microbial pathogens. Taken
together, these results concur with a scenario where the LKB1–
AMPK pathway acts as a signaling integrator that senses various
stressful conditions and converts this information into protectiveactivities for key cellular processes such as maintaining polarity
in epithelial cells.
5. Role of the LKB1/AMPK pathway in tumor suppression
The genetic dissection of the Peutz-Jeghers syndrome, tumor
mutational analyses and experimental models are consistent with
the identiﬁcation of LKB1 as a prototypical tumor suppressor [36].
However, the role of the AMPK pathway in safeguarding cells from
malignant transformation is less compelling. Novel ﬁndings pre-
sented in this review and additional data that we are going to
brieﬂy discuss, suggest that this question is not settled yet. Firstly,
studies in Drosophila have clearly showed that disruption of AMPK
leads to the outgrowth of tumor-like cells with disorganization of
cell polarity and abnormal mitotic ﬁgures [10,11]. Secondly, in
mammals, AMPK exerts several cellular functions that are expected
to restrain both tumor formation and progression, such as the inhi-
bition of the mTOR and lipid biosynthetic pathways that partici-
pate to the malignant process in a wide range of cancers [14].
Furthermore, AMPK induces mitochondrial biogenesis and in-
creases cell oxidative capacity, thereby antagonizing the malignant
metabolic reprogramming known as Warburg effect [14]. Finally,
there is mounting epidemiological evidence that the antidiabetic
drug metformin, an indirect AMPK activator, reduces the cancer
risks of treated patients [37]. According to this view, metformin
is endowed with anti-neoplastic properties in various experimen-
tal tumor settings [37].
Data obtained in Drosophila indicate that the LKB1–AMPK polar-
ity pathway converges on the activation of Myosin II that is likely
to impact on the contractile properties of the actomyosin cytoskel-
eton. What are the available arguments suggesting that this path-
way is involved in the LKB1 tumor suppressor function? As argued
in this review, there is substantial evidence that this pathway is
conserved in mammals. AMPK plays a role in F-actin remodeling
and contributes to cell polarization as exempliﬁed in the case of
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over, LS174T cells can be polarized by activation of either AMPK or
Myosin II [10]. Although these results do not prove that the LKB1–
AMPK–Myosin II pathway governs cell polarity in vivo in verte-
brates, they nevertheless constitute a robust indication that it is
the case. However, it is expected that AMPK does not mediate
LKB1-polarizing activities in every tissue, as already shown in neu-
rons [4,5]. A recent study of LKB1 function in pancreatic b cells has
also come to this conclusion by showing that LKB1–AMPK control
the size of b cells via the mTOR kinase but not their polarity [38].
Furthermore, during mitosis, the active form of AMPK is dynam-
ically localized in the centrosome, at the central spindle midzone
and in the midbody [39]. Based on experimental grounds, it has
been proposed that AMPK functions as a regulator of mitosis and
cytokinesis, ensuring the coordination between cellular energy re-
sources and genome division [40]. These results are consistent
with the genomic instability and aneuploidy of tumor-like cells
that develop in Drosophila AMPK mutants [10,11] and with a large
scale RNAi screening that aimed at identifying novel molecular ac-
tors involved in cell cycle progression [41]. Since Myosin II is an
essential component of the contractile ring that assembles at cyto-
kinesis, it is relevant to hypothesize that the LKB1–AMPK–Myosin
II acts as an energy-sensing checkpoint that controls completion of
cell division [42]. Thus, according to this scheme, the tumor sup-
pressor activity of this pathway would result from the intertwined
effect on cell polarity and cell division, two processes that could be
monitored by the LKB1–AMPK–Myosin II pathway and linked to
the energetic status of the cell. This model does not exclude other
AMPK functions, such as that the inhibition of cell growth, to ex-
plain the tumor suppressor function of LKB1. In this context, the
lack of identiﬁcation of recurrent bi-allelic inactivating mutations
in malignant tumors by the genome-wide cancer sequencing pro-
jects, which would constitute the formal demonstration that AMPK
is a tumor suppressor in human, may be related to the existence of
two genes encoding the catalytic alpha subunits and of several reg-
ulatory chains. This level of redundancy differs from Drosophila in
which a single gene encodes the catalytic subunit. Thus, the ques-
tion of the role of the LKB1–AMPK–Myosin II pathway in physio-
logical and pathophysiological processes in mammals will
certainly be the focus of future investigations. Following this line
of thinking, the recent identiﬁcation of a germline frameshift
mutation in the gene coding for the smooth-muscle myosin
(MYH11) in one PJS individual negative for LKB1 mutation, suggest
the intriguing idea that MYH11 could be a component of the LKB1
pathway [43]. If demonstrated, this result would support the no-
tion that LKB1 mediates its tumor suppressor activity, at least
partly, through the regulation of actin cytoskeleton dynamics and
its resulting effects on cell polarity and cell division.
Another indication that this pathway could be involved in tu-
mor suppression comes from the identiﬁcation of Dystroglycan
as part of the LKB1–AMPK polarity pathway. Down regulation of
Dg expression has been reported in many tumors [44–46]. Impor-
tantly, restoring normal expression of Dg in human tumor-derived
cell lines rescues their polarity defects and blocks their ability to
induce tumors in mice [47,48]. Although it is still not known
whether Dg plays a role in the LKB1/AMPK polarity pathway in hu-
man, these ﬁndings suggest that Dg contributes to the tumor sup-
pression effect of this pathway.
Finally, the molecular link between the metabolic state of the
cells and their polarity might be relevant in tumors. It is well doc-
umented that the access of tumor cells to key molecules used for
energy production (oxygen, glucose) can be limiting [49]. Thus, un-
der energetic stress conditions, the activation of the LKB1/AMPK
polarity pathway could be crucial to maintain the tissue microar-
chitecture and therefore to restrain tumor development.6. Conclusion
There are several pending questions that ought to be addressed
in the near future. Among them, one pressing issue concerns the
nature of the different components of the LKB1–AMPK–Myosin II
pathway. It is now ﬁrmly established that MRLCII is not a direct
AMPK substrate and it becomes important to deﬁne how this part
of the signaling network is laid out. In addition, it will be useful to
understand how Dystroglycan controls the localization of Myosin
II. It is doubtless that further clariﬁcation on how the components
of this newly described polarity pathway are interconnected in
cells and on its precise contribution to physiological processes as
well as to the protection against malignant development, will con-
stitute a fruitful area of research with promising applications in
cancer therapy.
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